Press Release
No. 3/2013

Zealand informs of new Sanofi scientific presentations for Lyxumia® and of own presentation of a novel Zealand liquid glucagon analogue at the ADA's 73rd Scientific Sessions

— Scientific data on the post-prandial mechanism of action of Lyxumia® to be presented

— Zealand to present own new data on a novel liquid glucagon analogue showing its potential to treat and/or prevent severe hypoglycemia

Copenhagen, 17 June 2013 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") informs of a series of data relating to Lyxumia® (lixisenatide), a GLP-1 receptor agonist discovered by Zealand and licensed globally to Sanofi, and of new data on a preclinical Zealand pipeline program to be presented at the American Diabetes Association's (ADA) 73rd Scientific Sessions taking place on 21-25 June 2013 in Chicago, US. The titles of the presentations follow.

Lyxumia®, the first once-daily prandial GLP-1 receptor agonist, is approved in the European Union for the treatment of adults with Type 2 diabetes mellitus to achieve glycemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control.

The Lyxumia® data to be presented at ADA will include pooled analyses investigating its post-prandial mechanism of action:

"Once-daily lixisenatide as add-on to basal insulin ± OADs in patients with Type 2 diabetes selectively reduces postprandial hyperglycemic daytime exposure" – Poster

When: Saturday, June 22, 11:30 am − 1:30 pm CDT
Presenter: M. Riddle, Oregon Health and Science University, Portland, USA.
Location: Poster Hall (will be available also as ePoster on the ADA website after press embargo lifting, Saturday 22 June, 10am CDT)

"Efficacy of lixisenatide in the GetGoal clinical trial program: pooled analysis of postprandial metabolic outcomes" – Abstract publication only

B. Ahrén, Lund University, Sweden.

Further data include analyses of the effects of Lyxumia® in combination with basal insulin on HbA_{1c}, weight gain and symptomatic hypoglycemia in patients with Type 2 diabetes:

"Expanding the basal-plus regimen: basal insulin + lixisenatide is more likely to achieve the composite outcome of HbA_{1c} <7%, no documented symptomatic hypoglycemia and no weight gain compared with basal + prandial insulin" – Poster

When: Saturday, June 22, 11:30 am − 1:30 pm CDT
Presenter: J. Rosenstock, Dallas Diabetes & Endocrine Center, Texas, USA
Location: Poster Hall (will be available also as ePoster on the ADA website after press embargo lifting, Saturday 22 June, 10am CDT)

"Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin in patients with type 2 diabetes mellitus" – Poster

When: Saturday, June 22, 11:30 am − 1:30 pm CDT
Presenter: B. Charbonnel, University of Nantes, France
Location: Poster Hall (will be available also as ePoster on the ADA website after press embargo lifting, Saturday 22 June, 10am CDT)

At the congress, Zealand will present preclinical data on ZP-GA-1, its own proprietary liquid glucagon analogue, which show the potential use for this compound in the treatment and/or prevention of severe hypoglycemia.

“A novel glucagon analogue, ZP-GA-1, displays increased chemical and physical stability in liquid formulation” – Poster

When: Sunday, June 23, 12:00 – 2:00 pm CDT
Presenter: D. Riber, Zealand, Denmark
Location: Poster Hall (will be available also as ePoster on the ADA website after press embargo lifting, Saturday 22 June, 10am CDT)

***

For further information, please contact:

David Solomon, President and Chief Executive Officer – Tel: +45 22 20 63 00

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of cardio-metabolic diseases, including diabetes and obesity, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved and launched (March 2013) in Europe under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA submission accepted in Feb 2013) and Japan (NDA filed in June 2012).

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: www.zealandpharma.com.
@ZealandPharma